Watch Prof. Charles Craddock discuss important and heartening results he and his team presented at the American Society of Hematology 2017 Annual Meeting and Exposition in Atlanta, GA – regarding whether there is effective salvage treatment (form of treatment given after an ailment does not respond to standard therapy) for patients with acute myeloid leukemia (AML) who recieve allogeneic stem cell transplantation. Read more about AML here.

This topic is of growing importance, because allogeneic stem cell transplantation is often the best form of treatment for AML – but relapse has been reported in as high as 70% of cases.

Craddock discusses the Phase I/II VIOLA study, which combine azacitidine and hide dose lenalidomide – which resulted in nearly 50% positive effect. This treatment option is safer/less strenuous than chemotherapy.

What are your thoughts on rare cancer treatments?? Share your stories, thoughts, and hopes, with the Patient Worthy community!